Search

Objective: The aim of this study was to investigate the effect on coronavirus disease-2019 (COVID-19) of glyoxal (GO), which is a precursor of advanced glycation end-products, in diabetic and non-diabetic patients, treated in hospital for COVID-19 who were of similar age and disease severity with similar comorbidities. Methods: The study included 57 patients. Measurement of GO was made with the high-performance liquid chromatography method. Results: The GO values were found to be higher in the diabetic group than in the non-diabetic group (p=0.001, p

Purpose: Biomarkers are useful measures assisting the diagnosis, treatment, and prognosis of cardiovascular diseases. They can predict the severity of cardiovascular diseases, especially in acute myocardial infarction at the emergency department. We aimed to investigate the severity of cardiovascular disease using three biomarkers, namely cardiac troponins, C-reactive protein (CRP), and procalcitonin in patients with ST-elevation myocardial infarction who presented to the emergency department. Materials and Methods: The study included a total of 166 patients that presented with ST-elevation myocardial infarction (STEMI) in the first three hours of symptom onset and underwent coronary angiography. SYNTAX (SS) scores were calculated, and based on these scores, two groups were formed. High-sensitivity troponin T (Hs-TnT), high-sensitivite CRP (Hs-CRP), and procalcitonin levels were measured at the presentation. Results: Although the high sensitive troponin, Hs-CRP values were higher in the SYNTAX score>20 groups, there was no statistically significant difference between the two groups. There was no significant difference in the PCT measurements between the two groups Conclusion: When Hs-TnT and Hs-CRP are evaluated together in patients with STEMI with a high SS, it may be predictive in early determining the severity of coronary artery disease.

Aim: Immune checkpoint inhibitors have transformed cancer treatment; however, clinical trials often exclude patients with renal dysfunction. This study aimed to evaluate the efficacy and safety of nivolumab in this population, addressing the limited available data. Methods: A retrospective cross-sectional study was conducted on patients with baseline renal dysfunction who received nivolumab between 2018 and 2023. The safety and efficacy endpoints, including immune-related adverse events (irAEs), treatment response, and progression-free survival. Results: Fifty patients with various malignancies were included, with 30% experiencing manageable worsening of renal function. Approximately 51% of patients experienced no irAEs, whereas 8% experienced grade 3 or 4 adverse events. The treatment discontinuation rate due to adverse effects was 2%. Significantly, 68% of patients showed treatment benefits, with a median progression-free survival of 450 days. Conclusion: Nivolumab is effective and safe for patients with renal dysfunction, with comparable outcomes to those without renal impairment. Despite the occurrence of IrAEs, they were manageable, and we observed benefits in long-term progression-free survival.